Acute Coronary Syndrome clinical trials at UCSD

1 research study open to eligible people

Milvexian in Participants After a Recent Acute Coronary Syndrome
open to eligible people ages 18 years and up
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
San Diego, California and other locations

Last updated: April 25, 2025